Combination of LIVERSTAT and Fibroscan-LSM outperforms FIB-4 and LSM for MASLD Advanced Fibrosis (F3F4) — multicenter easlfibronostg on June 29, 2026 Category: Publications Tag: Diabetes, Identification, LiverSTAT, MASLD Post navigation Previous: Previous post: LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patientsNext: Next post: Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)
